Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)‘s stock had its “outperform” rating reiterated by equities research analysts at Robert W. Baird in a report issued on Sunday. They presently have a $10.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s price objective suggests a potential upside of 129.36% from the company’s previous close. Several other brokerages […]
